Intellia Therapeutics' One-Time HAE Therapy Cuts Attacks 87% in Trial as FDA Decision Nears

Intellia Therapeutics (NTLA) reported that its one-time HAE therapy, lonvo-z, reduced attacks by 87% in trials. The company expects FDA decision soon. 88% of surveyed healthcare professionals would prescribe it. NTLA plans Q2 launch, with revenue recognition starting then. No price disclosed yet. About 7,500 U.S. patients are treated for HAE types 1 and 2.

Original reporting
Published Nov 12, 2026, 9:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 9:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Intellia Therapeutics' One-Time HAE Therapy Cuts Attacks 87% in Trial as FDA Decision Nears — source image
Decision brief

The 30-second read

$NTLABullishHigh
01

Why it matters

The 87% attack reduction data is a material clinical milestone that could accelerate FDA approval and commercial launch, influencing NTLA's valuation.

02

Market read

First‑time trial data creates a near‑term catalyst for NTLA; investors may act quickly on the news.

03

What to watch

Potential reimbursement hurdles and competition from other HAE therapies may temper upside.

Relevance 8/10Novelty 8/10Timing: immediate

Background

Intellia Therapeutics (NASDAQ:NTLA) is a CRISPR gene‑editing company developing a one‑time hereditary angioedema (HAE) therapy called lonvo‑z.

Company-level read

Ticker impact

$NTLABullishHigh confidence
Context

Intellia Therapeutics disclosed Phase 1‑3 trial data showing an 87% reduction in HAE attacks, a first‑time report that could move the stock.

Expected impact

likely upside as investors price in efficacy and near‑term FDA approval expectations

Evidence & confidence

The data is novel, first disclosed, and directly tied to a potential FDA decision, creating immediate catalyst risk.

Market effects

Boosts confidence in CRISPR‑based therapeutics and may lift peer biotech stocks.

U.S. biotech sector could see short‑term rally.

Limited to biotech investors; no broad macro effect.

Counterpoint

If FDA raises safety concerns or pricing issues, the stock could face sharp downside despite trial success.

Key entities

  • Intellia Therapeutics

    Clinical‑stage biotech developing CRISPR therapies.

  • FDA

    U.S. agency expected to decide on the therapy soon.

Related articles

$NTLAHighAI 8/10

Intellia stock price target maintained at $30 by Citizens on HAE data

Citizens maintained a $30 price target on Intellia Therapeutics (NTLA) after positive data on its lonvo-z treatment for hereditary angioedema. The firm noted strong patient demand and key opinion leader interest, with a sum-of-the-parts analysis valuing the HAE opportunity at $20 per share. NTLA trades at $10.55 with a market cap of $1.48 billion. The FDA granted Priority Review to lonvo-z, with a potential approval date of March 10, 2027.

$NTLALow

Intellia Therapeutics, Inc. (NTLA): Results of Operations and Financial Condition

Intellia Therapeutics, Inc. (NTLA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Readying Lonvo-z forPatients with HAE November 12, 2026 Exhibit 99.1 This presentation contains “forward-looking statements” of Intellia Therapeutics, Inc. (“Intellia”, “we” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-lookin

$NTLAMedAI 8/10

Intellia presents lonvo-z data at allergy conference

Intellia Therapeutics (NTLA) presented positive data on its hereditary angioedema treatment, lonvo-z, at a conference. The Phase 3 HAELO trial showed an 81% decrease in monthly attack rate. The Phase 1/2 study showed 100% of patients on a 50 mg dose were free from long-term prophylaxis, with 90% attack-free after one year. The FDA accepted the Biologics License Application with a target action date of March 10, 2027.

$NTLAMed

Intellia Therapeutics Announces Third Quarter 2026 Financial Results

Intellia Therapeutics, Inc. (NTLA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Intellia Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates - On track to complete lonvo-z commercial readiness efforts in advance of March 10, 2027 PDUFA date - New lonvo-z patient perspectives and Phase 1/2 durability data to be includ